Status In progress
Process MTA
Referral date June 2015

Provisional Schedule

Expected publication May 2017

Project Team

Project lead Kate Moore

Email enquiries


Companies sponsors Novartis (secukinumab)
  UCB Pharma (certolizumab)
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Psoriasis and Psoriatic Arthritis Alliance
  Psoriasis Association
Professional groups British Association of Dermatologists
  British Society for Rheumatology
  Primary Care Rheumatology Society
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians


Associated public health groups None
Comparator companies Abbvie
  Aspire Pharma (CAU not returned, not participating)
  Hameln pharmaceuticals (CAU not returned, not participating)
  Hospira UK (CAU not returned, not participating)
  Medac UK (CAU not returned, not participating)
  Merck Sharp & Dohme
  Orion Pharma UK (CAU not returned, not participating)
  Pfizer (CAU not returned, not participating)
  Sanofi (CAU not returned, not participating)
  Teva UK (CAU not returned, not participating)
  Zentiva UK (CAU not returned, not participating)
General commentators British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
Relevant research groups None


Key events during the development of the guidance:

Date Update
28 February 2017 Committee meeting: 3
22 December 2016 - 27 January 2017 Appraisal consultation: 2
25 October 2016 - 15 November 2016 Appraisal consultation
28 September 2016 Committee meeting: 1
16 December 2015 Invitation to participate
09 October 2015 Please note that the timelines for this MTA have been revised and we now anticipate that the appraisal will start in approximately mid December 2015. The deadline for submissions is expected in approximately mid April 2016.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance